The estimated Net Worth of David Schaffer is at least 17.7 百万$ dollars as of 20 October 2021. Dr Schaffer owns over 36,285 units of 4D Molecular Therapeutics stock worth over 14,167,100$ and over the last 8 years he sold FDMT stock worth over 3,386,060$. In addition, he makes 108,375$ as Co-Founder、 Chief Scientific Advisor & Independent Director at 4D Molecular Therapeutics.
Sign up
Dr D FDMT stock SEC Form 4 insiders trading
Dr has made over 7 trades of the 4D Molecular Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 36,285 units of FDMT stock worth 1,137,898$ on 20 October 2021.
The largest trade he's ever made was selling 36,285 units of 4D Molecular Therapeutics stock on 20 October 2021 worth over 1,137,898$. On average, Dr trades about 10,107 units every 124 days since 2017. As of 20 October 2021 he still owns at least 901,215 units of 4D Molecular Therapeutics stock.
You can see the complete history of Dr Schaffer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. David E. Schaffer Ph.D. biography
Dr. David E. Schaffer Ph.D. is the Co-Founder, Chief Scientific Advisor & Independent Director at 4D Molecular Therapeutics.
What is the salary of Dr D?
As the Co-Founder、 Chief Scientific Advisor & Independent Director of 4D Molecular Therapeutics, the total compensation of Dr D at 4D Molecular Therapeutics is 108,375$. There are 4 executives at 4D Molecular Therapeutics getting paid more, with Dr. David H. Kirn having the highest compensation of 701,533$.
How old is Dr D?
Dr D is 51, he's been the Co-Founder、 Chief Scientific Advisor & Independent Director of 4D Molecular Therapeutics since . There are 7 older and 1 younger executives at 4D Molecular Therapeutics. The oldest executive at 4D Molecular Therapeutics Inc. is August J. Moretti Esq., J.D., 70, who is the Chief Financial Officer.
What's Dr D's mailing address?
David's mailing address filed with the SEC is C/O 4D MOLECULAR THERAPEUTICS INC., 5858 HORTON STREET #455, EMERYVILLE, CA, 94608.
Insiders trading at 4D Molecular Therapeutics
Over the last 4 years, insiders at 4D Molecular Therapeutics have traded over 22,158,915$ worth of 4D Molecular Therapeutics stock and bought 2,479,347 units worth 51,074,981$ . The most active insiders traders include Global Investors Lp Viking ...、John F Milligan、Global Investors Lp Viking .... On average, 4D Molecular Therapeutics executives and independent directors trade stock every 36 days with the average trade being worth of 1,516,666$. The most recent stock trade was executed by Scott Bizily on 19 August 2024, trading 500 units of FDMT stock currently worth 3,245$.
What does 4D Molecular Therapeutics do?
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.
What does 4D Molecular Therapeutics's logo look like?
Complete history of Dr Schaffer stock trades at uniQure N.V、4D Molecular Therapeutics
4D Molecular Therapeutics executives and stock owners
4D Molecular Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. David H. Kirn,
Co-Founder, CEO, Pres & Director -
August J. Moretti Esq., J.D.,
Chief Financial Officer -
August J. Moretti,
Chief Financial Officer -
Dr. Robert S. Fishman,
Chief Medical Officer & Therapeutic Area Head of Pulmonology -
Dr. David E. Schaffer Ph.D.,
Co-Founder, Chief Scientific Advisor & Independent Director -
Dr. John F. Milligan,
Exec. Chairman -
Dr. Nadine Greiner Ph.D.,
Chief HR Officer -
Dr. Scott P. Bizily J.D., Ph.D.,
Chief Legal Officer -
Dr. Raphael Schiffmann M.D.,
Sr. VP & Therapeutic Area Head of Cardiology -
Jessica Wilan,
Sr. VP of HR -
Dr. Peter Francis B.Sc., M.D., Ph.D.,
Chief Scientific Officer & Head of Ophthalmology Therapeutic Area -
Dr. Fred Kamal Ph.D.,
COO & CTO -
Theresa Janke,
Co-Founder & Chief Strategy Officer -
Scott Bizily,
Chief Legal Officer -
August J Moretti,
Chief Financial Officer -
Tony Dung Ling Yao,
Director -
Noriyuki Kasahara,
Director -
Carolyne Zimmermann,
Chief Business Officer -
Robert Young Kim,
Chief Medical Officer -
Fariborz Kamal,
President and COO -
Uneek Mehra,
See Remarks -
David Schaffer,
Director -
Robert S Fishman,
Chief Medical Officer -
John F Milligan,
-
Susannah Gray,
-
Nancy Miller Rich,
-
David Kirn,
Chief Executive Officer -
Jacob Chacko,
-
Global Investors Lp Viking ...,
-
Charles Theuer,
-
Shawn Tomasello,